13Therapeutics Overview

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $999K

  • Investors
  • 5

13Therapeutics General Information

Description

Operator of drug development and research company intended to develop novel peptide therapeutics. The company leverages technology to identify, characterize and optimize anti-inflammatory peptide therapeutics, enabling healthcare professionals to better treat ailments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 4640 South West Macadam Avenue
  • Suite 200D
  • Portland, OR 97239
  • United States
+1 (503) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

13Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 01-Jan-2013 $999K Completed Startup
9. Grant 31-Dec-2016 00.000 Completed Startup
8. Grant 08-Jan-2016 00000 Completed Startup
7. Accelerator/Incubator Completed Startup
6. Grant 01-Jan-2012 00000 Completed Startup
5. Grant 01-Jan-2011 000000 Completed Startup
4. Grant 01-Jan-2008 00.000 Completed Startup
3. Grant 01-Jan-2007 00.000 Completed Startup
2. Grant 01-Jan-2006 $412K Completed Startup
1. Grant 01-Jan-2005 $385K Completed Startup
To view 13Therapeutics’s complete valuation and funding history, request access »

13Therapeutics Patents

13Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120258921-A1 Peptides for the treatment of hearing Active 06-Apr-2011 000000000 0
US-8580748-B2 Peptides for the treatment of hearing Active 06-Apr-2011 000000000 00
US-20140378395-A1 Peptides for the treatment of hearing Inactive 06-Apr-2011 000000000 0
US-20100317564-A1 Immunoregulatory peptides and methods of use Active 05-Jun-2009 0000000000 00
US-20130210741-A1 Immunoregulatory peptides and methods of use Active 05-Jun-2009 A61K39/285 0
To view 13Therapeutics’s complete patent history, request access »

13Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Steven Hefeneider Ph.D Chief Executive Officer, President & Board Member
Sharon McCoy Vice President of Product Development, Director of Research & Board Member
To view 13Therapeutics’s complete executive team members history, request access »

13Therapeutics Board Members (5)

Name Representing Role Since
Denis Burger Ph.D Self Board Member 000 0000
Sharon McCoy 13Therapeutics Vice President of Product Development, Director of Research & Board Member 000 0000
Steven Gillis Ph.D Self Board Member 000 0000
Steven Hefeneider Ph.D 13Therapeutics Chief Executive Officer, President & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

13Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

13Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
United States Department of Defense Government 000 0000 000000 0
Qualifying Therapeutic Discovery Project Not-For-Profit Venture Capital 000 0000 000000 0
National Institute for Allergy and Infectious Disease Government 000 0000 000000 0
National Institute on Deafness and Other Communication Disorders Government 000 0000 000000 0
OTRADI Bioscience Incubator Accelerator/Incubator 000 0000 000000 0
To view 13Therapeutics’s complete investors history, request access »

13Therapeutics FAQs

  • Who is the CEO of 13Therapeutics?

    Steven Hefeneider Ph.D is the CEO of 13Therapeutics.

  • Where is 13Therapeutics headquartered?

    13Therapeutics is headquartered in Portland, OR.

  • What is the size of 13Therapeutics?

    13Therapeutics has 4 total employees.

  • What industry is 13Therapeutics in?

    13Therapeutics’s primary industry is Drug Discovery.

  • Is 13Therapeutics a private or public company?

    13Therapeutics is a Private company.

  • What is 13Therapeutics’s current revenue?

    The current revenue for 13Therapeutics is 000000.

  • Who are 13Therapeutics’s investors?

    United States Department of Defense, Qualifying Therapeutic Discovery Project, National Institute for Allergy and Infectious Disease, National Institute on Deafness and Other Communication Disorders, and OTRADI Bioscience Incubator have invested in 13Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »